Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 4
2014 3
2015 2
2016 2
2017 1
2018 3
2019 2
2020 1
2021 3
2022 4
2023 2
2024 2
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial.
Branch DW, Kim MY, Guerra MM, Worden J, Laskin CA, DeSancho MT, Landres IV, Knight JS, Slosberg HS, Minett M, Salmon JE. Branch DW, et al. Ann Rheum Dis. 2025 Jun;84(6):1011-1022. doi: 10.1016/j.ard.2025.02.012. Epub 2025 Apr 10. Ann Rheum Dis. 2025. PMID: 40483169 Clinical Trial.
OBJECTIVES: The aim of this study was to evaluate whether certolizumab pegol, a tumour necrosis factor alpha inhibitor with little or no transport across the placenta, added to standard treatment with low molecular weight heparin plus low dose aspirin, reduce …
OBJECTIVES: The aim of this study was to evaluate whether certolizumab pegol, a tumour necrosis factor alpha inhibitor with li …
The Role of TNF-alpha and Anti-TNF-alpha Agents during Preconception, Pregnancy, and Breastfeeding.
Romanowska-Próchnicka K, Felis-Giemza A, Olesińska M, Wojdasiewicz P, Paradowska-Gorycka A, Szukiewicz D. Romanowska-Próchnicka K, et al. Int J Mol Sci. 2021 Mar 13;22(6):2922. doi: 10.3390/ijms22062922. Int J Mol Sci. 2021. PMID: 33805757 Free PMC article. Review.
Pregnancy poses a challenge in the treatment of chronic disease in patients who plan to have children. The activity of the disease, the impact of pregnancy on the course of the disease, and the safety of pharmacotherapy, including anti-rheumatic agents, in pregna …
Pregnancy poses a challenge in the treatment of chronic disease in patients who plan to have children. The activity of the disease, t …
Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis.
Lee A, Scott LJ. Lee A, et al. BioDrugs. 2020 Apr;34(2):235-244. doi: 10.1007/s40259-020-00416-z. BioDrugs. 2020. PMID: 32207094 Review.
Certolizumab pegol (Cimzia( )) is a PEGylated, Fab'-only, recombinant humanized antibody against TNF-alpha. ...In CIMPACT, certolizumab pegol 400 mg once every 2 weeks was superior to etanercept (highest recommended dosage) at 12 weeks, with certoli …
Certolizumab pegol (Cimzia( )) is a PEGylated, Fab'-only, recombinant humanized antibody against TNF-alpha. ...In CIMPACT, …
Summary of certolizumab pegol in psoriasis including structural features, pharmacokinetics and treatment.
Tokuyama M, Mabuchi T. Tokuyama M, et al. Immunotherapy. 2024 Mar;16(5):273-285. doi: 10.2217/imt-2023-0058. Epub 2024 Feb 6. Immunotherapy. 2024. PMID: 38319071 Review.
Among the five TNF-alpha inhibitors available for psoriasis, namely infliximab, adalimumab, etanercept, golimumab and certolizumab pegol (CZP), CZP has a unique mechanism of action due to its structure. As CZP lacks the Fc region, it does not cross the placenta …
Among the five TNF-alpha inhibitors available for psoriasis, namely infliximab, adalimumab, etanercept, golimumab and certolizumab …
Pregnancy Recommendations Solely Based on Preclinical Evidence Should Be Integrated with Real-World Evidence: A Disproportionality Analysis of Certolizumab and Other TNF-Alpha Inhibitors Used in Pregnant Patients with Psoriasis.
Gaio M, Vastarella MG, Sullo MG, Scavone C, Riccardi C, Campitiello MR, Sportiello L, Rafaniello C. Gaio M, et al. Pharmaceuticals (Basel). 2024 Jul 7;17(7):904. doi: 10.3390/ph17070904. Pharmaceuticals (Basel). 2024. PMID: 39065754 Free PMC article.
The most common pregnancy-related adverse event was spontaneous abortion, predominantly related to adalimumab and certolizumab. Certolizumab was also reported in cases of caesarean section, gestational diabetes, abortion, fetal death, fetal distress syndrome, …
The most common pregnancy-related adverse event was spontaneous abortion, predominantly related to adalimumab and certolizumab …
Rheumatic Diseases in Reproductive Age-the Possibilities and the Risks.
Grygiel-Górniak B, Masiero E, Nevaneeth BC, Jojy MM. Grygiel-Górniak B, et al. Reprod Sci. 2023 Jan;30(1):111-123. doi: 10.1007/s43032-022-00901-6. Epub 2022 Mar 31. Reprod Sci. 2023. PMID: 35359225 Review.
The literature search allowed us to form conclusions and underline recommendations regarding pregnancy's risk and treatment possibilities in the course of rheumatic disease. Optimal control of CTD activity should be reached at least 6 months before conception. ...Me …
The literature search allowed us to form conclusions and underline recommendations regarding pregnancy's risk and treatment po …
Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients.
Förger F, Zbinden A, Villiger PM. Förger F, et al. Joint Bone Spine. 2016 May;83(3):341-3. doi: 10.1016/j.jbspin.2015.07.004. Epub 2015 Nov 23. Joint Bone Spine. 2016. PMID: 26617214
OBJECTIVE: Due to reduction of immune-suppressive drugs, patients with rheumatic diseases can experience an increase in disease activity during pregnancy. In such cases, TNF-inhibitors may be prescribed. However, monoclonal antibodies with the Fc moiety are actively transp …
OBJECTIVE: Due to reduction of immune-suppressive drugs, patients with rheumatic diseases can experience an increase in disease activity dur …
Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease.
Chaparro M, Gisbert JP. Chaparro M, et al. Curr Pharm Biotechnol. 2011 May;12(5):765-73. doi: 10.2174/138920111795470903. Curr Pharm Biotechnol. 2011. PMID: 21342120 Review.
The aim of the present article was to review the role of the placenta function in the transfer of immunosuppressants and monoclonal antibodies used for the treatment of inflammatory bowel disease, as well as the available data regarding the safety of these therapies during …
The aim of the present article was to review the role of the placenta function in the transfer of immunosuppressants and monoclonal a …
A rheumatoid arthritis patient with delivery who started certolizumab pegol and tacrolimus during pregnancy.
Ito S, Ishikawa H, Kato R. Ito S, et al. Mod Rheumatol Case Rep. 2022 Jan 7;6(1):6-9. doi: 10.1093/mrcr/rxab005. Mod Rheumatol Case Rep. 2022. PMID: 34477867
We experienced a patient in her 30s with rheumatoid arthritis (RA) who achieved delivery with the use of certolizumab pegol (CZP) and tacrolimus (TAC) during pregnancy. She developed RA in X - 3 year and was treated with salazosulfapyridine (SASP). ...There i …
We experienced a patient in her 30s with rheumatoid arthritis (RA) who achieved delivery with the use of certolizumab pegol (C …
Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.
Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo RM, van Tubergen A, Shaughnessy L, Simpson J, Teil M, Helmer E, Wang M, Chakravarty EF. Mariette X, et al. Ann Rheum Dis. 2018 Feb;77(2):228-233. doi: 10.1136/annrheumdis-2017-212196. Epub 2017 Oct 13. Ann Rheum Dis. 2018. PMID: 29030361 Free PMC article. Clinical Trial.
OBJECTIVES: There is a need for effective and safe treatment during pregnancy in women with chronic inflammatory diseases. This study evaluated placental transfer of certolizumab pegol (CZP), an Fc-free anti-tumour necrosis factor drug, from CZP-treated pregn …
OBJECTIVES: There is a need for effective and safe treatment during pregnancy in women with chronic inflammatory diseases. This study …
27 results